PLRX — Pliant Therapeutics Income Statement
0.000.00%
Last trade - 00:00
- $711.42m
- $227.23m
- $1.58m
- 55
- 12
- 29
- 23
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | PROSPECTUS/A | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 57.1 | 41.8 | 7.57 | 9.69 | 1.58 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Total Operating Expenses | 58.3 | 83.5 | 105 | 137 | 186 |
Operating Profit | -1.23 | -41.6 | -97.5 | -127 | -184 |
Total Net Non Operating Interest Income / Expense | |||||
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -0.631 | -41.5 | -97.3 | -123 | -161 |
Net Income After Taxes | -0.631 | -41.5 | -97.3 | -123 | -161 |
Net Income Before Extraordinary Items | |||||
Net Income | -0.631 | -41.5 | -97.3 | -123 | -161 |
Adjustments to Net Income | |||||
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -6.86 | -41.5 | -97.3 | -123 | -161 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -0.2 | -1.95 | -2.71 | -2.94 | -2.75 |
Dividends per Share |